Nasus Pharma (NSRX) KOL event summary

Introduction and agenda

• The event focused on intranasal epinephrine for anaphylaxis, featuring presentations by KOLs and company leadership, followed by a Q&A session.

• The agenda included an overview of the company, market analysis, unmet needs for needle-free epinephrine, and clinical data review.

KOL background and credentials

• Dr. Michael Blaiss is a Clinical Professor of Pediatrics, past president of the American College of Allergy, Asthma and Immunology.

• Dr. Joel Brooks is an Assistant Professor of Pediatrics at Columbia University and active in allergy and immunology organizations.

Market insights and analysis

• Anaphylaxis prevalence is rising globally, with food allergies as a major driver, especially in children.

• The global epinephrine market is projected to double from $3B in 2024 to $6B by 2032, with the U.S. market expected to follow.

• Needle-free epinephrine options are gaining traction, with neffy showing strong first-year sales and patient adoption.

• Barriers to auto-injector use include needle fear, device size, and lack of training, leading to underuse and delayed treatment.